Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04533581 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 10 words
    • Publications: details revised at 1 of 1 entry
  2. Re-verified, no change to tracked fieldsv7
  3. Primary and study completion dates: Sep 30, 2024 to May 31, 2028v6
  4. Re-verified, no change to tracked fieldsv5
  5. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 60 to confirmed 61
    • Study sites: 1 to 30
    • Primary and study completion dates: Sep 2024 to Sep 30, 2024
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2020 to Sep 17, 2020
    • Site details revised
    v3
  2. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.
Trial Details
NCT Number NCT04533581
Lead Sponsor Kyowa Kirin Co., Ltd.
Conditions
(from sponsor)		 Indolent B-cell Non-Hodgkin's Lymphoma
Enrollment 61 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov